| Schedule of Segment Reporting Information, by Segment |
The following is a summary of our segment and consolidated net income (loss), including significant segment expenses: | | | | | | | Collaboration revenue | | | $21,000 | | | $— | | | $21,000 | | | $— | Less:
| | | | | | | | | | | | | General and administrative support | | | 6,678 | | | 3,486 | | | 11,250 | | | 7,309 | Clinical development | | | 3,047 | | | 5,710 | | | 6,690 | | | 10,039 | Research and discovery | | | 1,028 | | | 3,537 | | | 3,183 | | | 6,856 | Manufacturing | | | 218 | | | 2,610 | | | 1,792 | | | 6,698 | Other segment expenses(a) | | | 2,871 | | | 2,199 | | | 4,198 | | | 4,631 | | | | | | | | | | | | | | Interest income | | | 277 | | | 850 | | | 710 | | | 1,847 | Interest expense | | | (475) | | | (1,301) | | | (1,843) | | | (2,564) | Loss on extinguishment of note payable | | | (3,354) | | | — | | | (3,354) | | | — | Other income, net | | | 64 | | | 11 | | | 738 | | | 179 | Segment and consolidated net income (loss) | | | $3,670 | | | $(17,982) | | | $(9,862) | | | $(36,071) | | | | | | | | | | | | | |
(a)
| Other segment expenses includes non-cash expenses for stock-based compensation and depreciation expenses. |
|
The following is a summary of our segment and consolidated net loss, including significant segment expenses: | | | | Collaboration revenue | | | $— | | | $1,885 | Less: | | | | | | | Clinical development | | | 19,187 | | | 16,361 | Research and discovery | | | 12,660 | | | 14,389 | General and administrative support | | | 12,428 | | | 14,330 | Manufacturing | | | 8,523 | | | 19,759 | Other segment expenses(a) | | | 7,879 | | | 10,640 | Interest income | | | 3,108 | | | 6,673 | Interest expense | | | (5,274) | | | (4,656) | Loss on extinguishment of debt | | | — | | | (553) | Other income, net | | | 2,021 | | | 1,615 | Segment and consolidated net loss | | | $(60,822) | | | $(70,515) | | | | | | | |
(a)
| Other segment expenses includes non-cash expenses for stock-based compensation and depreciation expenses. |
|